Aeglea Biotherapeutics Financials

$99.8 M

Mkt cap, 16-Feb-2018
Net income (Q2, 2017)(6.6 M)
EBIT (Q2, 2017)(6.7 M)
Cash, 30-Jun-201726.9 M

Revenue/Financials

Income Statement

Annual

USDFY, 2016

R&D expense

18.1 m

General and administrative expense

8.4 m

Operating expense total

26.5 m

EBIT

(21.9 m)

Interest income

244 k

Net Income

(21.7 m)

Quarterly

USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

R&D expense

3.6 m4.4 m5.4 m4.9 m5.8 m

General and administrative expense

1.8 m2.4 m2.1 m2.4 m2.4 m

Operating expense total

5.4 m6.9 m7.5 m7.3 m8.2 m

EBIT

(4.6 m)(5.5 m)(6.3 m)(6.3 m)(6.7 m)

Interest income

26 k74 k72 k95 k100 k

Net Income

(4.5 m)(5.4 m)(6.2 m)(6.2 m)(6.6 m)

Balance Sheet

Annual

USDFY, 2016

Cash

47.7 m

Accounts Receivable

164.2 m

Inventories

1.7 m

Current Assets

66.4 m

PP&E

599 k

Total Assets

67.1 m

Accounts Payable

168 k

Current Liabilities

4 m

Total Liabilities

4.1 m

Additional Paid-in Capital

108.2 m

Retained Earnings

(45.3 m)

Total Equity

63 m

Financial Leverage

1.1 x

Quarterly

USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

24 m70.6 m49.5 m16.8 m26.9 m

Current Assets

35.2 m76.9 m71.7 m60.3 m66.2 m

PP&E

321 k377 k342 k822 k802 k

Total Assets

35.5 m77.3 m72.1 m61.3 m67.1 m

Accounts Payable

509 k348 k523 k267 k634 k

Current Liabilities

3.8 m3.4 m3.8 m4 m4.4 m

Total Liabilities

3.8 m3.4 m3.9 m4.1 m4.5 m

Additional Paid-in Capital

1.5 m107.5 m108 m108.7 m120.8 m

Retained Earnings

(28.1 m)(33.6 m)(39.8 m)(51.5 m)(58.2 m)

Total Equity

73.9 m68.2 m57.2 m62.6 m

Financial Leverage

1 x1.1 x1.1 x1.1 x

Cash Flow

Annual

USDFY, 2016

Net Income

(21.7 m)

Depreciation and Amortization

132 k

Accounts Receivable

(43.6 k)

Inventories

(96.1 k)

Accounts Payable

(8 k)

Cash From Operating Activities

(18.8 m)

Purchases of PP&E

(212 k)

Cash From Investing Activities

(12.1 m)

Cash From Financing Activities

49.4 m

Quarterly

USDQ1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(4.5 m)(5.4 m)(6.2 m)(6.2 m)

Accounts Payable

509 k348 k523 k267 k

Ratios

USDY, 2017

Financial Leverage

1.1 x
Report incorrect company information

Operating Metrics

FY, 2016

Nonclinical Development

3

Phase 1/2

1

Phase Approved

1

Phase I Trials

2
Report incorrect company information